At AACR 2026, multiple early-phase oncology readouts reinforced the sector’s continued focus on ADCs and targeted therapies in hard-to-treat populations. In separate presentations, researchers reported activity signals for a KRAS G12D inhibitor and for a CLDN6-targeting ADC in platinum-resistant ovarian cancer. In one study, early-phase data for zoldonrasib in KRAS G12D–mutant non-small cell lung cancer showed an objective response rate of 52% at the recommended Phase 2 dose, alongside a disease control rate of 93%, with the safety profile described as manageable. Another AACR presentation described first-in-human Phase I results for QLS5132, an antibody-drug conjugate targeting CLDN6 in advanced platinum-resistant ovarian cancer. The study reported partial responses in nine patients after dosing in an IV regimen every three weeks, with no treatment discontinuations or deaths attributed to adverse events in the summary. Together, the readouts highlight how ADC makers are aiming to preserve target-driven potency while managing systemic toxicity, while RAS-targeted drug developers pursue tumor genotype-defined strategies beyond the most common KRAS settings. For biotech professionals, the key takeaway is not late-stage efficacy but the early proof-of-concept signals and the dose-to-activity framing being used to justify Phase 2 expansion.